

**LIFE HEALTHCARE GROUP HOLDINGS LIMITED**

(Incorporated in the Republic of South Africa)

(Registration number: 2003/002733/06)

ISIN: ZAE000145892

JSE and A2X share code: LHC

("Life Healthcare" or "the Company")

**LIFE HEALTHCARE FUNDING LIMITED**

(Incorporated in the Republic of South Africa with limited liability)

(Registration number: 2016/273566/06)

LEI: 3789SJPQJZF8ZYXTZ394

Bond company code: LHFI

**DEALINGS IN SECURITIES BY LIFE HEALTHCARE, DIRECTORS, PRESCRIBED OFFICERS, DIRECTORS OF A MAJOR SUBSIDIARY AND THE COMPANY SECRETARY**

In terms of the Listings Requirements of JSE Limited, Life Healthcare shareholders and noteholders are hereby advised of the following dealings in securities under the rules of the Long-Term Incentive Plan ("the LTIP") and the Single Incentive Plan ("SIP").

Name of entity:	Life Healthcare
Nature of transaction:	On market purchase of shares
Class of securities:	Ordinary shares
Nature of interest:	Direct beneficial
Clearance obtained:	Yes

Date of transaction:	14 January 2025
Number of ordinary shares:	5,339,882
Volume weighted average price per share:	R16.0548
Highest price per share:	R16.4000
Lowest price per share:	R15.9000
The total value of the transaction:	R85,730,737.53

Date of transaction:	15 January 2025
Number of ordinary shares:	5,557,212
Volume weighted average price per share:	R16.1820
Highest price per share:	R16.3600
Lowest price per share:	R15.8800
The total value of the transaction:	R89,926,804.58

Date of transaction:	16 January 2025
Number of ordinary shares:	4,793,964
Volume weighted average price per share:	R16.2058
Highest price per share:	R16.3600
Lowest price per share:	R15.8800
The total value of the transaction:	R77,690,021.79



## 1. Long-Term Incentive Plan (“the LTIP”)

Shareholders and noteholders are reminded that on 15 and 16 March 2022, the Executive Directors, the Prescribed Officer, the Company Secretary and the Directors of the major subsidiaries of the Company accepted rights to participate in the Company’s Long-Term Incentive Plan (LTIP) – 2022 allocation.

The specified performance conditions related to this scheme have been met and vesting occurred on 31 December 2024.

The value of the vested performance shares in respect of the LTIP 2022 allocation was based on the performance outcomes and the 30-day VWAP as at 31 December 2024. The after-tax value has been utilised to purchase the shares. The number of LHC shares per participant was based on the average 3-day VWAP of 2,3 and 6 January 2025 of **R16.6793 (allocation value)**, which would have been the LHC share price had the Company been able to purchase the shares at that time.

A total of **5,835,437** of the purchased Life Healthcare shares have been acquired on market and will be transferred to the trading account of the respective recipients, based on the proportionate value vesting.

The number of shares to be delivered to the personal trading account on an off-market basis for the Executive Directors, the Prescribed Officer, the Company Secretary and the Directors of the major subsidiaries of the Company, respectively, which will be held directly beneficial, is as follows:

Details of recipient	Number of Life Healthcare Shares	Total Allocation Value at LHC share price of R16.6793
Peter Gerard Wharton-Hood – Director	460,116	R7,674,425.42
Petrus Phillippus van der Westhuizen – Director	327,490	R5,462,312.94
Adam Pyle – Prescribed Officer	227,393	R3,792,762.30
Kurt Wylie – Director of a major subsidiary of the Company	84,664	R1,412,138.58
Craig Koekemoer – Director of a major subsidiary of the Company	97,907	R1,633,022.91
Joshila Ranchhod – Company Secretary	66,202	R1,104,204.83

## 2. Single Incentive Plan (“the SIP”)

As previously communicated to the market, the board of directors of the Company has approved the introduction of the Single Incentive Plan, to incentivise and retain Eligible Employees. The first vesting of the FY2024 allocation occurred on 26 November 2024. The participants were awarded restricted Life Healthcare shares which will vest over the prescribed periods.

The calculation of the SIP was done by utilising the value of the deferral for each participant divided by the Company’s closing share price on 26 November 2024 of **R17.66**, after the Company’s financial year end results were announced. This would have been the purchase price per share had the Company not been in a closed period. In terms of this the total number of shares to be allocated to the individuals was **10,942,813**.



A total of **9,855,621** Life Healthcare shares were acquired on market at an average price of **R16.146** and a further **1,087,192** LHC shares was allocated from the shares held in trust from previously forfeited shares.

Below are the restricted shares allocated on an off-market basis to each of the Executive Directors, Prescribed Officer, Company Secretary and Directors of the major subsidiaries of the Company, which will be held directly as a beneficial shareholding in accordance with the respective vesting arrangements.

<b>Details of recipient</b>	<b>Vesting Period</b>	<b>Total Number of Life Healthcare Shares</b>	<b>Allocation value based on the LHC share price of R17.66</b>
Peter Wharton-Hood – Director	One third vesting in each of years 3,4 and 5	<b>1,016,965</b>	<b>R17,959,601.90</b>
Petrus Phillippus van der Westhuizen – Director	One third vesting in each of years 3,4 and 5	<b>670,724</b>	<b>R11,844,985.84</b>
Adam Mills Pyle – Prescribed Officer	One third vesting in each of years 3,4 and 5	<b>443,750</b>	<b>R7,836,625.00</b>
Joshila Ranchhod – Company Secretary	One third vesting in each of years 3,4 and 5	<b>264,884</b>	<b>R4,677,851.44</b>
Kurt Aston Wylie – Director of a major subsidiary of the Company	Full vesting after 3 years	<b>158,770</b>	<b>R2,803,878.20</b>
Craig Ian Koekemoer – Director of a major subsidiary of the Company	Full vesting after 3 years	<b>179,037</b>	<b>R3,161,793.42</b>

### **3. Matching Share Arrangement (“the MSA”)**

The vesting of the second tranche of the MSA occurred at the end of December 2024. The performance conditions, in respect of these shares have been met. The Human Resources and Remuneration Committee, via a majority, has approved the vesting. The closing price on date of Human Resources and Remuneration Committee approval, i.e. 9 January 2025 was used as the vesting price, which is **R15.81** per share.

The following shares will be delivered to the trading accounts on an off-market basis to each of the Directors and Prescribed Officer of the Company, which will be held directly beneficial as follows:

<b>Details of Recipient</b>	<b>Number of Life Healthcare Shares vesting</b>	<b>Total Value attributable to Award applying the cumulative average price of the share purchase of R15.81</b>	<b>LHC shares sold to cover tax liability</b>
Peter Gerard Wharton-Hood – Director	287,568	R4,546,450	-
Petrus Phillippus van der Westhuizen – Director	116,866	R1,847,651	53,544



Adam Mills Pyle – Prescribed Officer	65,073	R1,028,804	29,283
---	--------	------------	--------

Petrus Phillippus van der Westhuizen (Chief Financial Officer) has sold a portion of shares that have vested through the Company's MSA to settle the tax arising from the vesting:

Name of the Director:	Petrus Phillippus van der Westhuizen
Nature of transaction:	On market disposal of shares
Class of securities:	Ordinary shares
Nature of interest:	Direct beneficial
Clearance obtained:	Yes
Date of transaction:	15 January 2025
Number of securities:	<b>53,544</b>
Disposal price per share:	<b>R16.00</b>
Highest price per share:	R16.1700
Lowest price per share:	R16.1600
The total value of the transaction:	<b>R856,704</b>

Adam Mills Pyle (Chief Growth and Strategy Officer) has sold a portion of shares that have vested through the Company's MSA to settle the tax arising from the vesting:

Name of the Prescribed Officer:	Adam Mills Pyle
Nature of transaction:	On market disposal of shares
Class of securities:	Ordinary shares
Nature of interest:	Direct beneficial
Clearance obtained:	Yes
Date of transaction:	15 January 2025
Number of securities:	<b>29,283</b>
Disposal price per share:	<b>R16.1646</b>
Highest price per share:	R16.1700
Lowest price per share:	R16.1600
The total value of the transaction:	<b>R473,347.98</b>

Clearance to deal has been obtained for all the transactions above in terms of the Listings Requirements of the JSE.

Dunkeld  
20 January 2025

Equity Sponsor  
RAND MERCHANT BANK (A division of FirstRand Bank Limited)

Debt Sponsor  
Questco – Corporate Advisory